<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37338524</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Investigating the potential associated factors and developing a risk model for interstitial lung disease in Chinese patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>1000</EndPage><MedlinePgn>993-1000</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231182747</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to explore the risk factors for interstitial lung disease (ILD) in Chinese patients with systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This study recruited 40 SLE patients with ILD (SLE-ILD) and 40 SLE patients without ILD (SLE-non-ILD). Clinical data were collected from all patients, including basic clinical characteristics, affected organ systems, biochemical indexes, autoantibodies, and immunocytes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the SLE-non-ILD patients, SLE-ILD patients presented older age (<i>p</i> &lt; 0.001), dry cough (<i>p</i> = 0.006), "velcro-like" crackles (<i>p</i> = 0.021), Raynaud's phenomenon (<i>p</i> = 0.040), elevated complement 3 (C3) level (<i>p</i> = 0.044), and lower SLE disease activity index score (<i>p</i> = 0.013) and cluster of difference-3&#xa0;cell count (<i>p</i> = 0.043). Multivariate logistic regression analysis showed that older age (<i>p</i> &lt; 0.001, odds ratio [OR]: 1.212), female sex (<i>p</i> = 0.022, OR: 37.075), renal involvement (<i>p</i> = 0.011, OR: 20.039), C3 level (<i>p</i> = 0.037, OR: 63.126), immunoglobulin (Ig) M level (<i>p</i> = 0.005, OR: 5.082), and positive anti-U1 small ribonucleoprotein antibody (anti-nRNP) result (<i>p</i> = 0.003, OR: 19.886) were independent ILD risk factors in SLE patients. Consequently, the ILD risk model in patients with SLE was constructed based on statistically significant variables from the multivariate logistic regression analysis, which significantly correlated with ILD risk, with an area under the curve of 0.887 (95% confidence interval: 0.815-0.960) using receiver operating characteristic curve analysis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Age, female sex, renal involvement, C3 level, IgM level, and a positive anti-nRNP result are independent risk factors for ILD. Furthermore, their combination model is closely associated with an increased ILD risk in Chinese patients with SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, First Affiliated Hospital of Baotou Medical College, Baotou, China.</Affiliation><Identifier Source="RINGGOLD">540473</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Fuai</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, First Affiliated Hospital of Baotou Medical College, Baotou, China.</Affiliation><Identifier Source="RINGGOLD">540473</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Hongli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Le</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Pei</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4922-135X</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">biochemical index</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">risk model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37338524</ArticleId><ArticleId IdType="doi">10.1177/09612033231182747</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>